Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

BACKGROUND: Several studies have shown that darbepoetin alfa, an erythropoiesis-stimulating agent (ESA), can reduce transfusions and increase hemoglobin (Hb) levels in patients with chemotherapy-induced anemia (CIA). Recent safety concerns, however, have prompted changes to ESA product information....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Vansteenkiste, Johan, Hedenus, Michael, Gascon, Pere, Bokemeyer, Carsten, Ludwig, Heinz, Vermorken, Jan, Hamilton, Lisa, Bridges, Ken, Pujol, Beatriz
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2009
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2744706/
https://ncbi.nlm.nih.gov/pubmed/19728887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-311
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak